Distinguished in Polymyalgia Rheumatica

Christophe Richez

Bordeaux, FR 
Distinguished in Polymyalgia Rheumatica
Bordeaux, FR 
OverviewLocationsClinical Research

Overview

Christophe Richez practices in Bordeaux, France. Mr. Richez is rated as a Distinguished expert by MediFind in the treatment of Polymyalgia Rheumatica. His top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Systemic Lupus Erythematosus (SLE), and Rheumatoid Lung Disease.

His clinical research consists of co-authoring 196 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles and participated in 1 clinical trial in the study of Polymyalgia Rheumatica.

Gender
Male

Locations

Bordeaux, France
Other Locations
Lille, 59000, France
Brest, France
Strasbourg, France
Montpellier, France
Clermont-ferrand, France
Paris, France
Nantes, France
Limoges, France
Lyon, France
Pessac-sur-dordogne, 33600, France
Tours, 37000, France
Nancy, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
Soluble CD95 Ligand Role in the Pathophysiology of ANCA Associated Vasculitis
Soluble CD95 Ligand Role in the Pathophysiology of ANCA Associated Vasculitis
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Biological
Study Phase: Not Applicable
Involvement of Immune Cells Derived From the Intestine in Sjogren's Syndrome
Involvement of Immune Cells Derived From the Intestine in Sjogren's Syndrome
Enrollment Status: Completed
Publish Date: February 21, 2025
Intervention Type: Biological
Study Drugs: Blood sample, Biopsy of the labial salivary gland
Study Phase: Not Applicable
Randomized Placebo-controlled Trial Comparing Methotrexate vs. Methotrexate/Metformin Association in Rheumatoid Arthritis Patients
Randomized Placebo-controlled Trial Comparing Methotrexate vs. Methotrexate/Metformin Association in Rheumatoid Arthritis Patients
Enrollment Status: Active_not_recruiting
Publish Date: June 21, 2024
Intervention Type: Other, Drug
Study Drugs: Metformin, Methotrexate
Study Phase: Phase 2
O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus
O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: January 19, 2024
Intervention Type: Biological
Study Phase: Not Applicable
Dietary Phytoestrogens in Blood and Urine of Female Patient With Acute Systemic Lupus Erythematosus
Dietary Phytoestrogens in Blood and Urine of Female Patient With Acute Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: July 07, 2023
Intervention Type: Other
Study Phase: Not Applicable
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis
Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis
Enrollment Status: Completed
Publish Date: March 08, 2023
Intervention Type: Biological
Study Phase: Not Applicable
Cartography and Quantitative Characterization of Achilles Tendon Fibrocartilage by TE = 0ms Imaging at3T MRI
Cartography and Quantitative Characterization of Achilles Tendon Fibrocartilage by TE = 0ms Imaging at3T MRI
Enrollment Status: Completed
Publish Date: February 22, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Characterization of the Intestinal Microbiota in Patients With Inflammatory Bowel Disease and/or Spondyloarthritis and Study of the Impact of an Anti-TNF Alpha Therapy
Characterization of the Intestinal Microbiota in Patients With Inflammatory Bowel Disease and/or Spondyloarthritis and Study of the Impact of an Anti-TNF Alpha Therapy
Enrollment Status: Completed
Publish Date: May 26, 2022
Intervention Type: Other
Study Phase: Not Applicable
Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases
Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases
Enrollment Status: Completed
Publish Date: February 03, 2022
Intervention Type: Biological
Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE
Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE
Enrollment Status: Completed
Publish Date: December 04, 2020
Intervention Type: Drug
Study Phase: Phase 3
Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous
Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous
Enrollment Status: Completed
Publish Date: October 25, 2017
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 13 Less Clinical Trials

196 Total Publications

Pharmacology considerations for managing pregnancy in women with systemic lupus erythematosus.
Pharmacology considerations for managing pregnancy in women with systemic lupus erythematosus.
Journal: Expert review of clinical pharmacology
Published: October 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Richez's expertise for a condition
ConditionClose
View All 14 Advanced Conditions
View All 46 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile